232 related articles for article (PubMed ID: 32554237)
1. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
2. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
3. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
4. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
5. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
[TBL] [Abstract][Full Text] [Related]
6. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme - Data from a national neuro-oncology registry.
Hennessy MA; Coyne ZL; O'Halloran PJ; Mullally W; Dablouk M; MacNally S; Morris PG
J Clin Neurosci; 2022 Jan; 95():142-150. PubMed ID: 34929638
[TBL] [Abstract][Full Text] [Related]
8. Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.
Cahill DP
Neurosurg Clin N Am; 2021 Jan; 32(1):23-29. PubMed ID: 33223023
[TBL] [Abstract][Full Text] [Related]
9. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
Bunevicius A; Pikis S; Kondziolka D; Patel DN; Bernstein K; Sulman EP; Lee CC; Yang HC; Delabar V; Mathieu D; Cifarelli CP; Arsanious DE; Dahshan BA; Weir JS; Speckter H; Mota A; Tripathi M; Kumar N; Warnick RE; Peker S; Samanci Y; Barnett G; Hefnawi FE; Al Sideiri G; Sheehan J
J Neurooncol; 2021 Dec; 155(3):343-351. PubMed ID: 34797526
[TBL] [Abstract][Full Text] [Related]
11. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
Armocida D; Frati A; Salvati M; Santoro A; Pesce A
Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
[TBL] [Abstract][Full Text] [Related]
12. Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.
Tully PA; Gogos AJ; Love C; Liew D; Drummond KJ; Morokoff AP
Neurosurgery; 2016 Nov; 79(5):678-689. PubMed ID: 27409404
[TBL] [Abstract][Full Text] [Related]
13. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
14. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.
Ohno M; Miyakita Y; Takahashi M; Yanagisawa S; Tamura Y; Kawauchi D; Kikuchi M; Igaki H; Yoshida A; Satomi K; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2022 May; 17(1):85. PubMed ID: 35505351
[TBL] [Abstract][Full Text] [Related]
15. Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.
Dono A; Zhu P; Holmes E; Takayasu T; Zhu JJ; Blanco AI; Hsu S; Bhattacharjee MB; Ballester LY; Kim DH; Esquenazi Y; Tandon N
J Neurooncol; 2022 Jan; 156(2):353-363. PubMed ID: 34997451
[TBL] [Abstract][Full Text] [Related]
16. Survival and functional status after resection of recurrent glioblastoma multiforme.
Barker FG; Chang SM; Gutin PH; Malec MK; McDermott MW; Prados MD; Wilson CB
Neurosurgery; 1998 Apr; 42(4):709-20; discussion 720-3. PubMed ID: 9574634
[TBL] [Abstract][Full Text] [Related]
17. Repeat-surgery at Glioblastoma recurrence, when and why to operate?
Ening G; Huynh MT; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Sep; 136():89-94. PubMed ID: 26092644
[TBL] [Abstract][Full Text] [Related]
18. A clinical evaluation of cystic features in patients with newly diagnosed glioblastoma with IDH-wildtype.
Kim MJ; Park JS; Jeun SS; Ahn S
Clin Neurol Neurosurg; 2023 May; 228():107708. PubMed ID: 37043844
[TBL] [Abstract][Full Text] [Related]
19. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
20. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
